What is the 13F Pro Quality Score for ANIX?

13F Pro ranks Anixa Biosciences Inc (ANIX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ANIX's current score at https://13fpro.ai/company/ANIX (free sign-up required for the full ranking).

Where does 13F Pro source ANIX data?

All Anixa Biosciences Inc fundamentals and ownership data come directly from SEC EDGAR. Anixa Biosciences Inc files with the SEC under CIK 715446. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ANIX in?

Anixa Biosciences Inc (ANIX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ANIX research updated on 13F Pro?

ANIX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Anixa Biosciences Inc(ANIX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 715446 ANIX stock profile & AI dashboard →

13F Pro Quality Score

18.7/100

Rank #2,802 of 2,961 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why ANIX Scores 19/100

exact factor attribution · 2026-09-11

ANIX's composite is held back by free cash flow and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Institutional flow

-1.0 pts

31th pct

Earnings growth

-1.0 pts

30th pct

Earnings quality

-1.4 pts

36th pct

Shareholder dilution

-2.4 pts

1th pct

Scale

-3.0 pts

30th pct

Revenue growth

-4.0 pts

30th pct

Capital efficiency

-4.3 pts

7th pct

Profitability

-7.1 pts

3th pct

Free cash flow

-7.1 pts

2th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

Unusual Activity in ANIX

Events flagged as statistical outliers against ANIX's own multi-year baseline — not fixed dollar thresholds.

Insider cluster2026-07-31
2 insiders bought $139,798 of ANIX in 30 days — 3.7σ above this company's 2-year norm
View source filing →
Insider cluster2026-07-27
2 insiders bought $105,248 of ANIX in 30 days — 3.7σ above this company's 2-year norm
View source filing →

ANIX Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Anixa Biosciences Inc (ANIX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ANIX at 18.7/100 on a 32-signal composite quality model, placing it at rank #2,802 of 2,961 stocks — the bottom half of the AI-ranked universe. Top institutional holders of ANIX by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, UBS Group AG, Laird Norton Wetherby Company, based on the most recent SEC filings. ANIX trades on the Nasdaq exchange and files with the SEC under CIK 715446. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ANIX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Anixa Biosciences Inc directly from SEC EDGAR. Anixa Biosciences Inc's 13F Pro composite quality score has ranged between 19 and 27 since 2026, currently 18.7 — a declining long-term trajectory across 8 quarterly and live scoring snapshots.

✦

Fun facts about Anixa Biosciences Inc

Quirks, history, and lore behind ANIX — the kind of stuff that makes a stock memorable.

1
The Basics
A small-cap U.S. biopharmaceutical company listed on Nasdaq, headquartered in San Jose, California, focused on novel therapies for serious diseases.
2
The Numbers
With annual revenue in the single-digit millions and a market cap well under $100 million, this is a clinical-stage company betting big on future pipelines, not present profits.
3
The History
The company reinvented itself over the years, pivoting from earlier technology ventures into an oncology and infectious disease focused biotech — a classic small-cap transformation story.
4
The Secret
Its most buzzworthy program is a cancer vaccine — not a treatment, but an actual preventive vaccine for breast cancer — developed in partnership with a major research institution.
5
The Lore
It has collaborated with the Cleveland Clinic on that breast cancer vaccine, putting a tiny San Jose biotech in the same sentence as one of the world's most famous medical centers.
6
The Giveaway
Tick-borne illness, ovarian cancer, breast cancer vaccines — this Anixa-something company is swinging for the fences with a pipeline that could change preventive oncology forever.

▶ Think you know your stocks? Play the Daily Ticker

Net Income

Q2 2026

$-2.6M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

—FY 2025

FY22 —FY23 $210.0KFY24 $210.0KFY25 —

Net Income

+13.0% YoY

$-10.9MFY 2025

FY22 $-13.6MFY23 $-9.8MFY24 $-12.6MFY25 $-10.9M

Operating Income

+15.4% YoY

$-11.7MFY 2025

FY22 $-13.9MFY23 $-11.0MFY24 $-13.8MFY25 $-11.7M

EPS (Diluted)

+12.8% YoY

$-0.34FY 2025

FY22 $0.45FY23 $-0.32FY24 $-0.39FY25 $-0.34

Total Assets

-25.5% YoY

$16.1MFY 2025

FY22 $30.4MFY23 $25.5MFY24 $21.6MFY25 $16.1M

Op. Cash Flow

+2.2% YoY

$-7.2MFY 2025

FY22 $-6.5MFY23 $-6.2MFY24 $-7.3MFY25 $-7.2M

Free Cash Flow

—FY 2025

FY22 —FY23 —FY24 —FY25 —

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	—	$210.0K +0.0%	$210.0K	—	$512.0K	—
Net Income	$-10.9M +13.0%	$-12.6M -28.0%	$-9.8M +27.8%	$-13.6M -4.9%	$-13.0M -29.3%	$-10.0M
Operating Income	$-11.7M +15.4%	$-13.8M -25.6%	$-11.0M +20.6%	$-13.9M -5.6%	$-13.1M -31.6%	$-10.0M
EPS (Diluted)	$-0.34 +12.8%	$-0.39 -21.9%	$-0.32 -171.1%	$0.45	—	—
Total Assets	$16.1M -25.5%	$21.6M -15.4%	$25.5M -16.1%	$30.4M -16.1%	$36.3M +283.6%	$9.5M
Operating Cash Flow	$-7.2M +2.2%	$-7.3M -18.1%	$-6.2M +4.4%	$-6.5M -31.5%	$-4.9M +20.0%	$-6.2M
Free Cash Flow	—	—	—	—	—	$-6.2M

Get alerted when ANIX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Anixa Biosciences Inc including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ANIX

VANGUARD CAPITAL MANAGEMENT LLC
$3.7M1,329,852 sh
UBS Group AG
$1.6M585,430 sh
Laird Norton Wetherby Trust Company, LLC
$1.6M578,727 sh
D.A. DAVIDSON & CO.
$1.5M539,272 sh
GEODE CAPITAL MANAGEMENT, LLC
$1.0M359,194 sh
MARSHALL WACE, LLP
$919.3K328,332 sh
BlackRock, Inc.
$559.3K199,755 sh
VANGUARD FIDUCIARY TRUST CO
$538.6K192,356 sh
STATE STREET CORP
$445.3K159,040 sh
GSA CAPITAL PARTNERS LLP
$329.0K117,465 sh

Fund	Value	Shares
VANGUARD CAPITAL MANAGEMENT LLC	$3.7M	1,329,852
UBS Group AG	$1.6M	585,430
Laird Norton Wetherby Trust Company, LLC	$1.6M	578,727
D.A. DAVIDSON & CO.	$1.5M	539,272
GEODE CAPITAL MANAGEMENT, LLC	$1.0M	359,194
MARSHALL WACE, LLP	$919.3K	328,332
BlackRock, Inc.	$559.3K	199,755
VANGUARD FIDUCIARY TRUST CO	$538.6K	192,356
STATE STREET CORP	$445.3K	159,040
GSA CAPITAL PARTNERS LLP	$329.0K	117,465

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ANIX on your watchlist

Track score changes the day Anixa Biosciences Inc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ANIX a good stock to buy?

13F Pro's AI-powered analysis of Anixa Biosciences Inc (ANIX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ANIX are available on the ANIX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ANIX is classified as a small company.

Which hedge funds own ANIX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ANIX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Anixa Biosciences Inc's investment landscape.